ID   HKe-3
AC   CVCL_9796
SY   HKE-3; Hke-3; HKE3; Hke3
DR   BTO; BTO:0003469
DR   cancercelllines; CVCL_9796
DR   Wikidata; Q54889765
RX   PubMed=8465203;
RX   PubMed=9354428;
RX   PubMed=28192450;
CC   Population: Caucasian.
CC   Characteristics: In HCT 116 one of the two KRAS alleles has a p.Gly13Asp mutation. This cell line is KO for the mutant allele.
CC   Knockout cell: Method=Homologous recombination; HGNC; 6407; KRAS (Note=1 of 2 alleles).
CC   Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
DI   NCIt; C4910; Colon carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0291 ! HCT 116
SX   Male
AG   48Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 30-01-24; Version: 22
//
RX   PubMed=8465203; DOI=10.1126/science.8465203;
RA   Shirasawa S., Furuse M., Yokoyama N., Sasazuki T.;
RT   "Altered growth of human colon cancer cell lines disrupted at
RT   activated Ki-ras.";
RL   Science 260:85-88(1993).
//
RX   PubMed=9354428;
RA   Ohmori M., Shirasawa S., Furuse M., Okumura K., Sasazuki T.;
RT   "Activated Ki-ras enhances sensitivity of ceramide-induced apoptosis
RT   without c-Jun NH2-terminal kinase/stress-activated protein kinase or
RT   extracellular signal-regulated kinase activation in human colon cancer
RT   cells.";
RL   Cancer Res. 57:4714-4717(1997).
//
RX   PubMed=28192450; DOI=10.1371/journal.pone.0171435;
RA   Fasterius E., Raso C., Kennedy S., Rauch N., Lundin P., Kolch W.,
RA   Uhlen M., Al-Khalili Szigyarto C.;
RT   "A novel RNA sequencing data analysis method for cell line
RT   authentication.";
RL   PLoS ONE 12:E0171435-E0171435(2017).
//